{
      "Rank": 1,
      "Acronym": [
            "STEM-VAD"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "No"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [
            "No"
      ],
      "ArmGroupDescription": [
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart."
      ],
      "ArmGroupInterventionName": [
            "Biological: Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Other: Placebo"
      ],
      "ArmGroupLabel": [
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "<=18 years",
            "Between 18 and 65 years",
            ">=65 years",
            "Female",
            "Male",
            "Hispanic or Latino",
            "Not Hispanic or Latino",
            "Unknown or Not Reported",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported"
      ],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03925324"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [
            "United States"
      ],
      "BaselineDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineDenomCountValue": [
            "2",
            "2",
            "4"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Total of all reporting groups"
      ],
      "BaselineGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineGroupTitle": [
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Total"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants"
      ],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [
            "Age, Categorical",
            "Sex: Female, Male",
            "Ethnicity (NIH/OMB)",
            "Race (NIH/OMB)",
            "Region of Enrollment"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [
            "0",
            "0",
            "0",
            "1",
            "0",
            "1",
            "1",
            "2",
            "3",
            "0",
            "1",
            "1",
            "2",
            "1",
            "3",
            "0",
            "0",
            "0",
            "2",
            "2",
            "4",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "2",
            "2",
            "4",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "2",
            "2",
            "4"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices."
      ],
      "BriefTitle": [
            "Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "August 16, 2021"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Ischemic Heart Disease",
            "Non-ischemic Cardiomyopathy"
      ],
      "ConditionAncestorId": [
            "D000002318",
            "D000014652",
            "D000003327",
            "D000001161",
            "D000001157"
      ],
      "ConditionAncestorTerm": [
            "Cardiovascular Diseases",
            "Vascular Diseases",
            "Coronary Disease",
            "Arteriosclerosis",
            "Arterial Occlusive Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC14",
            "All",
            "BC23"
      ],
      "ConditionBrowseBranchName": [
            "Heart and Blood Diseases",
            "All Conditions",
            "Symptoms and General Pathology"
      ],
      "ConditionBrowseLeafAsFound": [
            "Cardiomyopathy",
            "Heart Disease",
            "Ischemic Heart Disease",
            "Ischemic Heart Disease"
      ],
      "ConditionBrowseLeafId": [
            "M11306",
            "M9695",
            "M8571",
            "M5698",
            "M18658",
            "M5701",
            "M16552",
            "M3621",
            "M3617"
      ],
      "ConditionBrowseLeafName": [
            "Cardiomyopathies",
            "Ischemia",
            "Heart Diseases",
            "Coronary Artery Disease",
            "Myocardial Ischemia",
            "Coronary Disease",
            "Vascular Diseases",
            "Arteriosclerosis",
            "Arterial Occlusive Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000006331",
            "D000009202",
            "D000017202",
            "D000003324"
      ],
      "ConditionMeshTerm": [
            "Heart Diseases",
            "Cardiomyopathies",
            "Myocardial Ischemia",
            "Coronary Artery Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "A double-blind, placebo-controlled, single-center, randomized study to assess the safety and preliminary efficacy of a three serial intravenous doses of allogeneic mesenchymal bone marrow cells to subjects with heart failure and implanted left ventricular assist devices."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nAge \u226518 years.\nAdvanced Heart Failure\nAdvanced HF defined as HF requiring LVAD implantation and deemed stable on his/her LVAD.\nOn stable medical therapy (per the discretion of the treating physician) including beta-blockers, ACE-inhibitors, angiotensin receptors blockers, angiotensin receptor neprilysin inhibitor, mineralocorticoid receptor antagonists, isosorbide, hydralazine, and mineralocorticoid receptor antagonists) and optimized pump speed for at least a month prior to randomization.\nHS-CRP level\u22652 mg/l.\nNYHA class II-III symptoms.\nAbility to understand and provide signed informed consent.\nReasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits\n\nExclusion Criteria:\n\nWomen of childbearing potential. Postmenopausal women or women with permanent contraception method (defined as total hysterectomy) will not be excluded.\nHistory of debilitating stroke (modified Rankin Score > 3) within 3 months.\nThe likelihood of requirement of cardiac surgery during the study period.\nPresence of clinically significant, uncorrected left sided valvular heart disease, active acute myocarditis, or uncontrolled hypertension defined as Persistently elevated mean arterial blood pressure (>100 mmHg). Echocardiography within 12 months of screening. Patients can be re-evaluated, at the discretion of the investigator.\nQTc >550 ms (in the absence of bundle branch block, interventricular conduction delay or ventricular pacing). Electrocardiogram (ECG) within 60 days.\nHistory of cardiac arrest within 3 months.\nHypertrophic or infiltrative cardiomyopathy.\nConsidered or listed for organ transplantation or history of organ transplantation\nIllness other than HF with life expectancy less than 12 months.\nEnrolled in an interventional trial or received an experimental drug or device within 30 days of randomization.\nLeft ventricular assist device implantation >2 years prior to enrollment.\nBiventricular assist device (Bi-VAD) support.\nSevere COPD defined by FEV1<1L, FEV1/FVC<70% within 12 months if known history of COPD, otherwise FEV1<1L, FEV1/FVC<70% within 24 months\nUncontrolled seizure disorder.\n\nClinically significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests within the last 30 days:\n\nLiver disease = ALT or AST > 3x normal, alkaline phosphatase or bilirubin >2x normal Renal disease = on long term dialysis Hematologic = Unexplained persistent leukocytosis (WBC >11 K/UL) or hemoglobin < 8.5 gm/dl\n\nPresence of any other clinically-significant medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the investigator or sponsor may affect compliance with the study protocol or pose a safety risk to the subject.\nInability to comply with the conditions of the protocol.\nAcute coronary syndrome within 4 weeks (clinical diagnosis, confirmed by electrocardiographic abnormalities and elevation of troponin-I).\nMalignancy within the previous five years, except adequately treated basal cell carcinoma, provided that it is neither infiltrating nor sclerosing, and carcinoma in situ of the cervix.\nActive uncontrolled systemic infection. Positive blood or deep tissue cultures or clinical or imaging evidence of systemic infection despite complete course of effective antimicrobial therapy as determined by infectious diseases. Localized (non-systemic) infection is not an exclusion criterion. Patients can be re-evaluated, at the discretion of the investigator.\nEarly postpartum cardiomyopathy (within six months of diagnosis).\nPresence of inherited or acquired immune deficiency or human immunodeficiency virus infection (HIV). Negative HIV test within the preceding 12 months is required.\nSystemic corticosteroids, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, tacrolimus, azathioprine, mycophenolate, sirolimus, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment.\nKnown Porphyria.\nAllergy to sodium citrate or any caine type of local anesthetic.\nPatient enrolled in hospice care."
      ],
      "EnrollmentCount": [
            "4"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "1",
            "1"
      ],
      "EventGroupDeathsNumAtRisk": [
            "2",
            "2"
      ],
      "EventGroupDescription": [
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution"
      ],
      "EventGroupId": [
            "EG000",
            "EG001"
      ],
      "EventGroupOtherNumAffected": [
            "2",
            "2"
      ],
      "EventGroupOtherNumAtRisk": [
            "2",
            "2"
      ],
      "EventGroupSeriousNumAffected": [
            "2",
            "2"
      ],
      "EventGroupSeriousNumAtRisk": [
            "2",
            "2"
      ],
      "EventGroupTitle": [
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo"
      ],
      "EventsDescription": [
            "Clinicaltrials.gov definitions used."
      ],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [
            "1 year post randomization"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowAchievementNumSubjects": [
            "2",
            "2",
            "1",
            "1",
            "1",
            "1"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [
            "Death"
      ],
      "FlowGroupDescription": [
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution"
      ],
      "FlowGroupId": [
            "FG000",
            "FG001"
      ],
      "FlowGroupTitle": [
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [
            "FG000",
            "FG001"
      ],
      "FlowReasonNumSubjects": [
            "1",
            "1"
      ],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M21013"
      ],
      "InterventionBrowseLeafName": [
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "1.5 mL/kg Lactated Ringer's Solution"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [
            "March 23, 2020"
      ],
      "LargeDocFilename": [
            "Prot_SAP_000.pdf"
      ],
      "LargeDocHasICF": [
            "No"
      ],
      "LargeDocHasProtocol": [
            "Yes"
      ],
      "LargeDocHasSAP": [
            "Yes"
      ],
      "LargeDocLabel": [
            "Study Protocol and Statistical Analysis Plan"
      ],
      "LargeDocTypeAbbrev": [
            "Prot_SAP"
      ],
      "LargeDocUploadDate": [
            "12/30/2021 14:14"
      ],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "February 2, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 3, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Medstar Health Research Institute"
      ],
      "LimitationsAndCaveatsDescription": [
            "Due to lack of funding and COVID-19, the study was terminated early after 4 patients were recruited. This number is too small to perform any analysis"
      ],
      "LocationCity": [
            "Washington"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "MedStar Washington Hospital Center"
      ],
      "LocationState": [
            "District of Columbia"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "20010"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of the Safety and Efficacy of Intravenous Delivery of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients and Implanted Left Ventricular Assist Device"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Medstar Health Research Institute"
      ],
      "OrgStudyId": [
            "STEMVAD-001"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [
            "Respiratory, thoracic and mediastinal disorders",
            "Cardiac disorders",
            "Musculoskeletal and connective tissue disorders",
            "Cardiac disorders",
            "Infections and infestations",
            "Musculoskeletal and connective tissue disorders"
      ],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "OtherEventStatsNumAffected": [
            "1",
            "0",
            "2",
            "1",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1"
      ],
      "OtherEventStatsNumAtRisk": [
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2"
      ],
      "OtherEventStatsNumEvents": [
            "1",
            "0",
            "2",
            "1",
            "1",
            "0",
            "0",
            "2",
            "0",
            "1",
            "0",
            "1"
      ],
      "OtherEventTerm": [
            "Non-Productive Cough",
            "Sub-Therapeutic INR",
            "Lower Back Pain",
            "LAVD Alarm Issue",
            "PICC Line Replacement",
            "Back/Shoulder/Neck Pain"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeDenomCountValue": [
            "0",
            "0",
            "0",
            "0",
            "2",
            "2",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution",
            "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.\n\nHuman Allogeneic Mesenchymal Bone Marrow Cells (aMBMC): Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg",
            "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.\n\nPlacebo: 1.5 mL/kg Lactated Ringer's Solution"
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeGroupTitle": [
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo",
            "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Placebo"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "Temperature",
            "Number of admission for uncontrolled systemic infection",
            "Rate of Death",
            "percent reduction in NK cells",
            "The change in the lab values N-Terminal Prohormone of Brain Natriuretic Peptide (NT-ProBNP)",
            "Change in RV systolic function",
            "Number of hospitalizations for to right heart failure",
            "6 minute walk distance changes",
            "Count of gout flares"
      ],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [
            "Count of Participants"
      ],
      "OutcomeMeasurePopulationDescription": [
            "Due to study termination and small sample size, no analysis was performed",
            "Due to study termination and small sample size, no analysis was performed",
            "Due to study termination and small sample size, no analysis was performed",
            "Due to study termination and small sample size, no analysis was performed",
            "Due to study termination and small sample size, no analysis was performed",
            "Due to study termination and small sample size, no analysis was performed",
            "Test was not performed for any subjects at 90 days, therefore no changes could be analyzed",
            "Due to study termination and small sample size, no analysis was performed"
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "up to 12 months post enrollment",
            "up to 12 months post enrollment",
            "up to 12 months post enrollment",
            "Baseline to day 90",
            "Baseline and day 90 post initial infusion",
            "Baseline and day 90 post initial infusion",
            "day 90",
            "Baseline and day 90 post initial infusion",
            "Day 90"
      ],
      "OutcomeMeasureTitle": [
            "Temperature",
            "Uncontrolled Systemic Infection",
            "All-cause Mortality",
            "NK Cell Depletion",
            "Change in the Following Cardiac Biomarker",
            "Change in RV Systolic Function",
            "Hospitalizations Due to Right Heart Failure",
            "6 Minute Walk Distance Changes",
            "Gout Flares"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Primary",
            "Primary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "Participants"
      ],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG001"
      ],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [
            "1",
            "1"
      ],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Terminated"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [
            "megan.e.rowland@medstar.net"
      ],
      "PointOfContactOrganization": [
            "Medstar Health Research Institute"
      ],
      "PointOfContactPhone": [
            "202-877-2959"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Megan Rowland"
      ],
      "PrimaryCompletionDate": [
            "August 16, 2021"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Temperature",
            "Number of admission for uncontrolled systemic infection",
            "Rate of Death"
      ],
      "PrimaryOutcomeMeasure": [
            "Temperature",
            "Uncontrolled Systemic Infection",
            "All-cause Mortality"
      ],
      "PrimaryOutcomeTimeFrame": [
            "up to 12 months post enrollment",
            "up to 12 months post enrollment",
            "up to 12 months post enrollment"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [
            "February 2, 2022"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "January 3, 2022"
      ],
      "ResultsFirstSubmitQCDate": [
            "January 3, 2022"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "percent reduction in NK cells",
            "The change in the lab values N-Terminal Prohormone of Brain Natriuretic Peptide (NT-ProBNP)",
            "Change in RV systolic function",
            "Number of hospitalizations for to right heart failure",
            "6 minute walk distance changes",
            "Count of gout flares"
      ],
      "SecondaryOutcomeMeasure": [
            "NK Cell Depletion",
            "Change in the Following Cardiac Biomarker",
            "Change in RV Systolic Function",
            "Hospitalizations Due to Right Heart Failure",
            "6 Minute Walk Distance Changes",
            "Gout Flares"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Baseline to day 90",
            "Baseline and day 90 post initial infusion",
            "Baseline and day 90 post initial infusion",
            "day 90",
            "Baseline and day 90 post initial infusion",
            "Day 90"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "SeriousEventNotes": [
            "Admitted for Esophageal obstruction, later diagnosed with esophageal cancer",
            "Fluid overload"
      ],
      "SeriousEventOrganSystem": [
            "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "Gastrointestinal disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Renal and urinary disorders",
            "Cardiac disorders",
            "Infections and infestations"
      ],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "SeriousEventStatsNumAffected": [
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1"
      ],
      "SeriousEventStatsNumAtRisk": [
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2",
            "2"
      ],
      "SeriousEventStatsNumEvents": [
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1"
      ],
      "SeriousEventTerm": [
            "Esophageal Obstruction/Cancer",
            "PEG Placement",
            "Abdominal Pain/Hematemesis",
            "Acute Chronic Heart Failure",
            "Sub Therapeutic INR",
            "Acute on Chronic Renal Failure",
            "Ventricular Tachycardia",
            "MRSA Bacteremia"
      ],
      "StartDate": [
            "May 3, 2019"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 24, 2019"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "April 1, 2019"
      ],
      "StudyFirstSubmitQCDate": [
            "April 19, 2019"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": [
            "Lack of funding/Covid-19"
      ]
}